Kymera Therapeutics, Inc. (KYMR) – What Are Investment Firms Thinking About This Stock?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned a consensus rating of “Moderate Buy” from the twenty-seven analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $134.68.

Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They issued a “hold” rating and a $120.00 target price for the company. Truist Financial lifted their price target on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, June 29th. TD Cowen raised Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Mizuho boosted their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Raymond James Financial started coverage on Kymera Therapeutics in a research note on Thursday, October 8th. They issued an “outperform” rating and a $140.00 price objective on the stock.

Kymera Therapeutics Trading Up 0.1%

NASDAQ:KYMR opened at $106.83 on Friday. Kymera Therapeutics has a 1-year low of $55.26 and a 1-year high of $130.05. The firm has a fifty day simple moving average of $115.21 and a 200 day simple moving average of $100.78. The stock has a market capitalization of $8.88 billion, a PE ratio of -32.97 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same period in the previous year, the company earned ($0.95) earnings per share. The firm’s revenue for the quarter was up 465.2% on a year-over-year basis. On average, equities analysts predict that Kymera Therapeutics will post -3.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider directly owned 50,254 shares in the company, valued at $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 15.98% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. NorthCrest Asset Manangement LLC acquired a new stake in Kymera Therapeutics during the third quarter worth approximately $258,000. GAMMA Investing LLC boosted its holdings in shares of Kymera Therapeutics by 79.3% during the third quarter. GAMMA Investing LLC now owns 814 shares of the company’s stock worth $91,000 after acquiring an additional 360 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Kymera Therapeutics by 657.0% during the second quarter. Squarepoint Ops LLC now owns 97,189 shares of the company’s stock worth $11,145,000 after acquiring an additional 84,350 shares during the period. Nykredit A S acquired a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $207,000. Finally, Allianz Asset Management GmbH acquired a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $516,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.

Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.